Collegium Pharmaceutical Appoints Vikram Karnani as CEO
Company Announcements

Collegium Pharmaceutical Appoints Vikram Karnani as CEO

Collegium Pharmaceutical ( (COLL) ) has shared an announcement.

Vikram Karnani has been appointed as the new CEO of Collegium Pharmaceutical, effective November 12, 2024, succeeding Michael Heffernan, who continues as Chairman. Karnani brings extensive experience from Amgen and Horizon Therapeutics, positioning Collegium for its next growth phase following the acquisition of Ironshore Therapeutics. Under his leadership, the company aims to capitalize on record revenues and expand its presence in neurology with Jornay PM® as a key growth driver.

For detailed information about COLL stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyCollegium Pharmaceutical reports Q3 adjusted EPS $1.61, consensus $1.59
TheFlyCollegium Pharmaceutical sees FY24 net product revenues of $620M-$635M
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App